title: Sphingosine-1 phosphate and central nervous system.
abstract: The development of fingolimod, an unselective functional antagonist of the interactions between sphingosine 1 phosphate (S1P) and sphingosine 1 phosphate receptors (S1PRs), as the first oral therapy for multiple sclerosis (MS) has been a milestone. The parallel intensive research on the role of S1P, sphingosine kinases, and the five known S1PRs, their tissue distribution and expression in physiological and pathological conditions have led to a wide range of interesting findings. The initial focus of this research in the context of developing fingolimod as a treatment of MS has been on its immunological effects. The wide distribution and important roles of sphingosine, its metabolites, and their receptors in the central nervous system (CNS) in general, in myelin, and in all cell types of this organ have spurred interest to examine S1P and its five receptors in the brain as well. The present review will concentrate on the latter area and give a brief overview of what is known about S1P/S1PR interactions in the CNS in physiological and pathological conditions.
authors.affiliation: Neuroimmunology and Multiple Sclerosis Research, Clinic for Neurology, University Hospital Zurich, University Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland, Roland.Martin@usz.ch.
authors.forename: Roland
authors.initials: R
authors.lastname: Martin
authors.forename: Mireia
authors.initials: M
authors.lastname: Sospedra
mesh_terms: D000818:Animals; D002493:Central Nervous System Diseases / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D008246:Lysophospholipids / Q000819:agonists / Q000378:metabolism / Q000627:therapeutic use*; D049349:Receptors, Lysosphingolipid / Q000378:metabolism; D013110:Sphingosine / Q000819:agonists / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use
chemical_list: D008246:Lysophospholipids; D049349:Receptors, Lysosphingolipid; C060506:sphingosine 1-phosphate; D013110:Sphingosine